Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : MLSC Blood decontaminant recieves patent!!! -- Ignore unavailable to you. Want to Upgrade?

To: Cindy Powell who wrote (188)	11/29/2000 1:06:50 PM
From: Cindy Powell	Respond to of 196

Howdy folks, MLSC Receives $500,000 in Funding. I'm still holding my shares, and am still hoping that they get things going. More news and activity is much needed for us longs. MLSC states that funding is achieved because there is a fundamental belief in the possibility for MDI-P, and while I share that belief, I think they better improve shareholder relations and launch a more effective investor relations campaign. People are left in the dark too much with this company and are losing faith and patience. Monday November 20, 4:45 pm Eastern Time Press Release SOURCE: Medical Discoveries, Inc. MDI Receives Funding to Continue Studies of MDI-P; Medical Discoveries, Inc. Signs Agreement with Peregrine Properties, LLC SALT LAKE CITY, Nov. 20 /PRNewswire/ -- Medical Discoveries, Inc. (OTC Bulletin Board: MLSC - news) announced today that Peregrine Properties, LLC has agreed to provide $500,000 to fund critical testing and research steps necessary to continue development of MDI's primary product, an anti-viral (HIV/AIDS), anti-bacterial and anti-fungal drug named MDI-P. Under terms of the agreement, MDI will continue to study the toxicology and chemistry of the drug and conduct laboratory and clinical studies of the drug's efficacy. The research activities will be directed by Dr. William J. Novick, MDI's Vice President and Chief Technical Officer. Upon completion of the studies, Peregrine Properties, LLC will receive 5.5 million shares of common stock and representation on MDI's Board of Directors in exchange for ownership of the studies and results. Peregrine Properties is a Utah limited liability company organized in March, 1996. Peregrine Properties is a development company owned by J. Douglass Bowers and Carl R. Faulkner. The primary business activity of the company has been real estate development. According to Carl Faulkner, ``the investment in the research for MDI's continued development of MDI-P was made to facilitate the completion of the studies, unencumbered by any other pressures. We believe in the future of MDI and their products. We are convinced that the research studies will demonstrate the potential good of MDI-P for the world.'' Formed in 1991, Medical Discoveries, Inc. is a development-stage biopharmaceutical research company engaged in the research, development and validation of a new class of drugs, based upon the company's patented and proprietary electrolysis technologies. MDI is developing active anti-viral (HIV/AIDS), anti-bacterial and anti-fungal agents for a variety of applications. Information in this press release relating to the potential of MDI-P constitutes forward-looking statements. Actual results in future periods may differ materially from the forward-looking statements because of a number of risks and uncertainties, including but not limited to the Company's unproved products, capital requirements, competition, and governmental regulation. Additional information about these and other factors that could affect the Company's business is set forth in the Company's 1999 Annual Report on Form 10-KSB and other filings with the Securities and Exchange Commission. SOURCE: Medical Discoveries, Inc. Email this story - Most-emailed articles - Most-viewed articles -------------------------------------------------------------------------------- More Quotes and News: Medical Discoveries Inc (OTC BB:MLSC.OB - news) Related News Categories: biotech, medical/pharmaceutical --------------------------------------------------------------------------------